Advertisement

Tumor Biology

, Volume 35, Issue 1, pp 369–377 | Cite as

Quantitative assessment of the association between +61A>G polymorphism of epidermal growth factor gene and susceptibility to glioma

Research Article

Abstract

Numerous studies have investigated the risk of cancer associated with the polymorphism of epidermal growth factor (EGF) 61A>G, but results have been inconsistent. We performed this meta-analysis to drive a more precise estimation of the association between this polymorphism and risk of glioma. A comprehensive search was conducted to identify all case–control studies on the EGF +61A>G polymorphism and glioma risk. Odds ratios (ORs) and 95 % confidence intervals (95 % CIs) were calculated to assess the strength of the association. Statistical analysis was performed with the software program Stata (version 12.0). A total of ten eligible studies, including 1,888 cases and 2,836 controls were included in this work. Overall, there was a significant association between EGF +61A>G polymorphism and glioma risk in the allele model (OR = 1.419, 95 % CI = 1.144–1.759, P = 0.001). In the subgroup analysis by ethnicity, significant associations were also found in Asian populations under all different genetic models (homozygote model: OR = 1.727, 95 % CI = 1.310–2.275, P = 0.000; heterozygote model: OR = 1.202, 95 % CI = 1.023–1.413, P = 0.025; dominant model: OR = 1.279, 95 % CI = 1.096–1.491, P = 0.002; recessive model: OR = 1.590, 95 % CI = 1.221–2.070, P = 0.001; and A-allele versus G-allele OR = 1.600, 95 % CI = 1.145–2.236, P = 0.006). However, no significant associations were found among Caucasians in all comparison models. In conclusion, the results suggest that there is a significant association between EGF +61A>G polymorphism and glioma risk among Asians.

Keywords

Epidermal growth factor Glioma Polymorphism Meta-analysis 

Notes

Conflicts of interest

None

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRefGoogle Scholar
  2. 2.
    Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005;109:93–108.PubMedCrossRefGoogle Scholar
  3. 3.
    Kleihues P, Cavanee WK. Pathology and genetics of tumours of the nervous system. 2nd ed. Lyon: IARC; 2000.Google Scholar
  4. 4.
    Butowski NA, Sneed PK, Chang SM. Diagnosis and treatment of recurrent high-grade astrocytoma. J Clin Oncol. 2006;24:1273–80.PubMedCrossRefGoogle Scholar
  5. 5.
    Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973–1991. J Neurosurg. 1998;88:1–10.PubMedCrossRefGoogle Scholar
  6. 6.
    Normanno N, Bianco C, De Luca A, Salomon DS. The role of EGF-related peptides in tumor growth. Front Biosci. 2001;6:D685–707.PubMedCrossRefGoogle Scholar
  7. 7.
    Laurence DJ, Gusterson BA. The epidermal growth factor. A review of structural and functional relationships in the normal organism and in cancer cells. Tumour Biol. 1990;11:229–61.PubMedCrossRefGoogle Scholar
  8. 8.
    Fenstermaker RA, Ciesielski MJ. Deletion and tandem duplication of exons 2–7 in the epidermal growth factor receptor gene of a human malignant glioma. Oncogene. 2000;19:4542–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Sauter G, Maeda T, Waldman FM, Davis RL, Feuerstein BG. Patterns of epidermal growth factor receptor amplification in malignant gliomas. Am J Pathol. 1996;148:1047–53.PubMedGoogle Scholar
  10. 10.
    Shahbazi M, Pravica V, Nasreen N, Fakhoury H, Fryer AA, et al. Association between functional polymorphism in EGF gene and malignant melanoma. Lancet. 2002;359:397–401.PubMedCrossRefGoogle Scholar
  11. 11.
    Bhowmick DA, Zhuang Z, Wait SD, Weil RJ. A functional polymorphism in the EGF gene is found with increased frequency in glioblastoma multiforme patients and is associated with more aggressive disease. Cancer Res. 2004;64:1220–3.PubMedCrossRefGoogle Scholar
  12. 12.
    Xu W, Li Y, Wang X, Chen B, Liu S, et al. Association between EGF promoter polymorphisms and cancer risk: a meta-analysis. Med Oncol. 2010;27:1389–97.PubMedCrossRefGoogle Scholar
  13. 13.
    Zhang YM, Cao C, Liang K. Genetic polymorphism of epidermal growth factor 61A.G and cancer risk: a meta-analysis. Cancer Epidemiol. 2010;34:150–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Xin X. Lei Xi, Jie Zeng, Qinhong Yao: A functional +61G/a polymorphism in epidermal growth factor is associated with glioma risk among Asians. PLoS One. 2012;7(7):e41470.CrossRefGoogle Scholar
  15. 15.
    Costa BM, Ferreira P, Costa S, Canedo P, Oliveira P, Silva A, et al. Association between functional EGF+ 61 polymorphism and glioma risk. Clin Cancer Res. 2007;13:2621–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Vauleon E, Auger N, Benouaich-Amiel A, Laigle-Donadey F, Kaloshi G, Lejeune J, et al. The 61 A/G EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma. Cancer Genet Cytogenet. 2007;172:33–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Pinto GR, Yoshioka FK, Clara CA, Santos MJ, Almeida JR, Burbano RR, et al. Association study of an epidermal growth factor gene functional polymorphism with the risk and prognosis of gliomas in Brazil. Int J Biol Markers. 2009;24:277–81.PubMedGoogle Scholar
  18. 18.
    Liu X, Li L, Chen X, Wang X, Mu L, Li Y, et al. No association between EGF +61 A/G polymorphism and increased risk of glioma. Int J Biol Markers. 2009;24:77–82.PubMedGoogle Scholar
  19. 19.
    Wang S, Zhao Y, Ruan Z, Chen H, Fan W, Chen J, et al. Association between EGF +61 G/A and glioma risk in a Chinese population. BMC Cancer. 2010;10:221.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Bao G, Wang M, Guo S, Han Y, Xu G. Association between epidermal growth factor +61 G/A polymorphism and glioma risk in a Chinese Han population. J Int Med Res. 2010;38:1645–52.PubMedCrossRefGoogle Scholar
  21. 21.
    Muthusamy KA, Lian LH, Vairavan N, Chua KH, Waran V. Genetic polymorphisms of EGF 5′-UTR and NAT2 857G/A associated with glioma in a case control study of Malaysian patients. Genet Mol Res. 2012;11:2939–45.PubMedCrossRefGoogle Scholar
  22. 22.
    Li Y, Zhao Y, Liu J, Liu P, Xu Y. A functional polymorphism in the epidermal growth factor gene is associated with risk for glioma in a Chinese population. Genet Test Mol Biomarkers. 2012;16:449–52.PubMedCrossRefGoogle Scholar
  23. 23.
    da Silveira F, Lopes Bde A, da Fonseca CO, Quirico-Santos T, de Palmer Paixao IC, de Amorim LM. Analysis of EGF +61A>G polymorphism and EGF serum levels in Brazilian glioma patients treated with perillyl alcohol-based therapy. J Cancer Res Clin Oncol. 2012;138:1347–54.PubMedCrossRefGoogle Scholar
  24. 24.
    Skoog T, van't Hooft FM, Kallin B, Jovinge S, Boquist S, Nilsson J, et al. A common functional polymorphism (C–>A substitution at position −863) in the promoter region of the tumor necrosis factor-alpha (TNF-alpha) gene associated with reduced circulating levels of TNF-alpha. Hum Mol Genet. 1999;8:1443–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Momparler RL, Bovenzi V. DNA methylation and cancer. J Cell Physiol. 2000;183:145–54.PubMedCrossRefGoogle Scholar
  26. 26.
    Shen H, Wang L, Spitz MR, Hong WK, Mao L, Wei Q. A novel polymorphism in human cytosine DNA-methyltransferase-3B promoter is associated with an increased risk of lung cancer. Cancer Res. 2002;62:4992–5.PubMedGoogle Scholar
  27. 27.
    Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19:183–232.PubMedCrossRefGoogle Scholar
  28. 28.
    Jin G, Miao R, Deng Y, et al. Variant genotypes and haplotypes of the epidermal growth factor gene promoter are associated with a decreased risk of gastric cancer in a high-risk Chinese population. Cancer Sci. 2007;98:864–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Lanuti M, Liu G, Goodwin JM, et al. A functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcome. Clin Cancer Res. 2008;14:3216–22.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Lim YJ, Kim JW, Song JY, et al. Epidermal growth factor gene polymorphism is different between schizophrenia and lung cancer patients in Korean population. Neurosci Lett. 2005;374:157–60.PubMedCrossRefGoogle Scholar
  31. 31.
    Kang HG, Choi JE, Lee WK, et al. +61A>G polymorphism in the EGF gene does not increase the risk of lung cancer. Respirology. 2007;12:902–5.PubMedCrossRefGoogle Scholar
  32. 32.
    Vishnoi M, Pandey SN, Modi DR, et al. Genetic susceptibility of epidermal growth factor +61A>G and transforming growth factor β1-509C>T gene polymorphisms with gallbladder cancer. Hum Immunol. 2008;69:360–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Spindler KL, Nielsen JN, Ornskov D, et al. Epidermal growth factor (EGF) A61G polymorphism and EGF gene expression in normal colon tissue from patients with colorectal cancer. Acta Oncol. 2007;46:1113–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Kang S, Kim JW, Park NH, et al. Epidermal growth factor 61 A/G polymorphism and uterine cervical cancer. Int J Gynecol Cancer. 2007;17:492–6.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  1. 1.Department of NeurosurgeryGeneral Hospital of Shenyang Military Area CommandShenyangChina

Personalised recommendations